Anautomated "high-pressure" liquid-chromatographic assay forhemoglobinA1 is described.We use a 45-mm incubation in acetate buffer (pH 5.5) to eliminate labile glycated hemoglobins.In this automated system conventionalmodulesare usedbut it incorporates a solvent-switching valve to select eitheroftwo buffers, which differ in pH and NaCI concentration. The chromatographic column contains "polyCAT" (a weak cation-exchanger, polyasparticacid linked to silica). Run time is 14 mm per sample. The method is precise and results correlate well with those by other ion-exchange procedures.
HbA1 (Hb-glucose 6-phosphate adduct), HbAlb (probably a deamidation product of Hb), and HbA1 (primarily Glib modified at the /3-terminal valines). However, not all the material that is eluted in the HbA1 peak binds to affinity columns, indicating that the peak does not represent a single component (3). Moreover, affinity columns react with material making up about 5% of the HbA0 peak obtained after purification by ion-exchange, which probably reflects Hb that is glycated at sites other than /3-chain N-terminal valines (3). Despite these differences in the fractions detected by the different methods, there is a useful clinical correlation between GHb results obtained by ion-exchange and by affinity column or colorimetric methods, unless molecular charge is affected by N-terminal carbamylation in uremia, acetylation in chronic therapy with salicylate, penicilloylation in therapy with antibiotics, the presence of 5-deoxyxylulose 1-phosphate adducts in alcoholics, or amino acid modifications in some hemoglobinopathies, as reviewed by Gabbay (13) and others (4, 9).
Several authors have described liquid-chromatographic
(HPLC) systems for separating hemoglobins.
All have used cation-exchange chromatography on various supports such as BioRex-70, which contains a weak carboxylic acid function (14-18); polyCAT, which also has a carboxylic acid function in the form of polyaspartic acid linked to silica (19, 20) ; a silica-based carboxymethyl polyamide solid phase (21-24); or "Micropearl," an ion-exchange resin of undisclosed structure, used with the Daiichi analyzer (25, 26) . Columns of BioRex give less-satisfactory resolution than do silica-based columns. Flow rate is limited by the compressibility of the resin and its non-uniform size. It may be necessary to reverse the columns frequently because expansion and contraction of the resin in response to the changing ionic composition of the mobile phase causes distortion of the column bed and deterioration of chromatographic performance. BioRex-70 columns for HPLC are usually prepared in the laboratories in which they are used because they currently are not available commercially; this limits their utility for routine laboratories. In view of the excellent precision reported in the literature for HPLC methods for HbA1, and the improved resolution of the newer columnpacking materials such as polyCAT as compared with that of BioRex-70, we chose to adapt the method of Ou et al. (19) , which was designed for the separation of variant hemoglobins to the routine analysis for HbA1. Our method has twice the throughput of that of Ou et al. and does not require an HPLC gradient-generating accessory. We describe here our method and illustrate the critical variables affecting separation of HbA1 by HPLC.
Materials and Methods Equipment
We use a liquid-chromatographic system with spectrophotometric detection at 405 nm. This comprises a wispy" 
Reagents
Buffer A: 40 mmolIL phosphate, pH 6.30, containing 60 mmol/L NaCI, 5 mmolIL NaCN, and 0.5 mL/L Triton X-100. Dissolve 10.88 g of KH2PO4, 7.02 g of NaC1, and 0.490 g of NaCN in approximately 1900 mL of water, adjust the pH to 6.30 with 5 mol/L and 0.5 mol/L KOH, and adjust the volume to 2 L. Recheck the pH. Filter through a Millipore Type HA 0.45-pm ifiter. Transfer to a 2-L polyethylene bottle containing a magnetic stir bar. While mixing continuously, slowly add 1 mL of Triton X-100 (alkylaryl polyether alcohol) from a pipette, with the tip placed just beneath the surface of the buffer. Leave the solution mixing for a further 5 to 10 mm to dissolve all the Triton. De-gas the buffer by somcation in a waterbath for 10 mm. This buffer is stable at room temperature for one week. Recheck the pH before reuse.
Caution.

NaCN is toxic. Follow safety regulations
concerning the safe storage, use, and disposal of buffers and HPLC effluent containing cyanide. Blood samples. Collect blood by venipuncture, using EDTA as anticoagulant.
Blood may be stored at 4#{176}C for four days (27) to one week (9) before analysis.
Quality-control
bloods. We found that commercially available lyophilized controls were unsuitable for quality-control purposes. The HPLC pattern was quite different from that for fresh blood, and samples often showed multiple abnormal tailing peaks. Consequently we prepared our own controls as follows:
Pipette into 12 x 75 mm polystyrene tubes 200 50-L aliquots of blood from each of three individuals with HbA1 approximately 5%, 10%, and 15% of total hemoglobin, add 2 mL of 150 mmol!L NaCI to each, mix, and incubate for 5 h at 37 #{176}C. Centrifuge at 1400 x g for 10 mi decant the saline, and stopper the tubes. Transfer the washed erythrocytes to a -70 #{176}C freezer. On the day the samples are to be used, add 4 mL of Buffer A, mix, transfer to a 5-mL syringe, and ifiter through a disposable Millex#{174}-HV 0.45-pm ifiter unit (Millipore Ltd., Mississauga, Ont., Canada).
Samples are stable for at least six months at -70 #{176}C. Storage at -10 to -20 #{176}C is unsatisfactory (9). We have not evaluated an alternative method of stabilizing the Hb by use of ethylene glycol (28) , but laboratories that do not have access to -70 #{176}C freezers may choose to assess this method.
Procedure
Mix the blood sample and pipette 50 pL into a 12 x 75 mm polystyrene tube. Add 2 mL of acetate solution, mix, and incubate for 45 mm in a 37#{176}C air oven to remove the labile fraction of glycated hemoglobin. Centrifuge the suspensions at 1400 x g for 10 mm. Decant the acetate. Add 4 mL of Buffer A. Mix well to resuspend the erythrocytes, which are rapidly lysed by the Triton X-100 in the buffer.
Transfer the hemolysate to a 5-mL syringe, filter through the disposable filter unit, and collect about 1.5-2.0 mL in a wisp sample vial and the remainder in a 12 x 75 mm polystyrene tube as a back-up hemolysate. Cap the wisp vial and load it on the sampler. Cap and store the back-up hemolysate at 4#{176}C for as long as four weeks, if necessary. conserve buffer and will take effect only at the end of the run because the timer is normally reset after each injection. Set the spectrophotometer to 405 nm. Select an area-percent plot on the integrator with optimum integration parameters. We find that with a 1-V input on the LCI-100, the optimum parameters are: peak width value 6, area sensitivity 30, baseline sensitivity 8, baseline drawn through base points, print tolerance >3% of total area, chart speed 5 mm/mm, attenuation 32 giving full-scale deflection of 0.032 A, offset 5%, force baseline at 13.9 mm. Select tick marks on the printout to denote the areas included in the calculated area, because these are a valuable form of quality controlsee Results section. Program the wisp sampler to inject 20 pL of each sample. Load the wisr carousel with vials containing the hemolysates.
Chromatographic Conditions
Run high, medium, and low quality-control samples at the start and end of each run. The chromatographic patterns should resemble those shown in Figure 1 .
Preparation of a New Column
When a mew column is first used, wash it with distilled water for 1 h, then with Buffer A for 1 h. Test a qualitycontrol sample with 14-16% HbA1 six to 10 times, using the recommended procedure, until the chromatographic pattern shows good resolution of the HbA1 peak ( Figure 1 ) and acceptable accuracy and precision are achieved, if this does not occur, make minor adjustments to the composition of Buffer A or adjust the column temperature as discussed later.
Results
Developmentof Method
Choice of column. Two columns were tested initially. One was a 6 x 125 mm column packed with a methacrylic acid copolymer (10-pm particle size) having weak (unspecified) cation-exchange properties, Early experiments gave similar resolution on the two columns with slightly different chromatographic conditions. However, the po1yCAT column cost approximately half as much and consequently we used this column in most of our development work. After the method had been in routine use for several months, we experienced some difficulties with a batch of polyCAT columns, which prompted us to test a Protein Pak SP 5PW 7.5 x 75 mm sulfopropyl column from Waters Scientific. Different buffer systems were required for this column and the conditions and results will be briefly presented later.
Column life. After 200-600 injections, resolution deteriorates; the A1,, peak becomes broader and tails. When this occurs, the integrator does not resolve the HbA1,, peak from that which immediately follows it, and this peak is included in the A1,, area (as indicated by the positioning of the "tick" marks on the integrator). This results in poor reproducibility and generally an increase in the fraction of the Hb reported as the HbA1,,. The error may represent 0.5-3% of total hemoglobin.
Choice of buffers and time sequence of buffer changes.
Note: It has been our experience with columns supplied by Custom LC Inc. that different columns prepared from the same batch of packing material have very similar properties. However, those prepared from different batches of polyCAT may have sufficiently different retentivity to necessitate minor changes in the pH or NaCl concentration of Buffer A or necessitate the use of increased column temperature to produce satisfactory resolution of HbA1,,.
Fast hemoglobins (HbAja, HbAlb, HbA1,,) are less readily retained by cation-exchange resins than is HbA0. We did not have a gradient apparatus on our HPLC, so we wished to use conditions under which the fast hemoglobins were resolved with use of a suitable buffer (Buffer A), after which the remaining hemoglobins (usually mainly the A0 fraction) were rapidly eluted by use of a high salt./pH buffer (Buffer B). Time is then needed to re-equilibrate the column in preparation for the next injection. Using the recommended buffers, and with the equipment we describe, the selection of Buffer B at 0.5 mm gives the chromatography shown in Figure 1 (some time is needed to ifil the pump and column  with the new buffer) . Selection of Buffer B after 0.5 mm delays the elution of the hemoglobin A0 peak, but does not improve resolution. Approximately 5-6 mm of elution with Buffer B at the recommended flow rate of 1.3 mL/min is required to elute the A0 peak. An 8-mn wash with Buffer A re-equilibrates the column in preparation for the next sample. if this time is shortened, re-equilibration does not take place and the fast Hb fractions elute too early. By use of relatively high pH and high-molarity Buffer B and with buffer changes at 0.5 and 6.0 mm, the composition of Buffer A can be critically adjusted. At 60 mmol!L NaCl, pH has a marked influence on elution (Figure 2) . At pH 6.1 and 6.2 the retention times of HbAia, HbAlb, HbA1. are increased, resolution of HbAia and HbAlb is improved, but the HbA1 has not completely eluted before HbA0 elutes. [The small unknown peak that follows the I{bA1,, is not seen. It probably co-elutes with HbA0 under those conditions, because a similar HbA1 value was obtained at pH 6.2 as at pH 6. satisfactory.
The A0 peak was much sharper and showed less tailing with use of cyanide. Triton X-100 was included to prevent protein and lipid buildup within the system (29) . At concentrations of 0.5 mLIL, but not 0.1 milL or less, it improved resolution and peak sharpness ( Figure 2F ). At 2 mIlL and greater, the increased concentration caused foaming.
Removal of the labile fraction of glycated Hb. In our early experiments, we added 2 mL of 150 mmoLfL NaC1 to 50 1L of blood, mixed, and incubated at 37 #{176}C for 5 h to remove the labile fraction. Bannon (30) showed that 200 mmoLfL acetate, pH 5.5, removes the labile fraction in 30 mm at 37 #{176}C. We wished to use a buffer such that the residual buffer on the erythrocytes after decantation would negligibly affect the pH of our liquid-chromatography system. if the concentration of the pH 5.5 acetate is lowered to 10 to 100 mmoLfL, there is some hemolysis. We therefore diluted the 200 mmoLfL acetate with three volumes of 150 mmoIJL NaC1 to maintain a suitable osmolality. When we obtained a sample from a patient with poorly controlled diabetes mellitus and incubated it in the acetate buffer containing NaC1 that we recommend, we observed a decrease in measured HbA1,, from 19. 3% (without incubation) to 16.2, 16.0, 15.9, 16.0 Hemolysate preparation. The method described is fast and convenient. We chose to wash the serum proteins from the erythrocytes to minimize the protein load on the column and eliminate any possible interference by bilirubin (9). We chose a simple wash with 40 times the blood volume rather than the traditional two washes with twice the blood volume, to shorten the labor time. We chose to hemolyze with Buffer A (containing Triton X-100) so that the pH of the hemolysate would resemble the chromatographic buffer into which it was injected. We wished to avoid a separate extraction with organic solvent (8, 14, 15 ) to remove the erythrocyte membranes after hemolysis. Filtration through Millex filters is rapid and effective. One Millex ifiter (22 mm in diameter) will filter the erythrocyte membranes from 50 L of lysed blood with a normal hematocrit before the ifiter pores become plugged.
Effect of sample volume. Variations in the amount of hemoglobin injected into the system have little effect on the result. If the patient is grossly anemic, or the blood was not adequately anticoagulated and a very dilute sample of erythrocytes is sampled from around a clot, then an inaccurate result may be obtained. Such hemolysates can often be identified visually. The total area calculated by the integrator may also be examined, and should be within ±30% of the mean area. Prepare more concentrated hemolysates from such patients by use of more erythrocytes or less buffer. At very low hemoglobin concentration, the integrator distinguishes peak boundaries less readily. if the hemoglobin is greatly increased, the column is overloaded with protein and the quality of the chromatographic separation deteriorates. When the volume of a hemolysate from a normal subject was varied between 5 and 100 L, optimum separation was achieved with 10-to 20-giL injections.
Effect of temperature. We routinely ran our system at room temperature (24-28 #{176}C) without temperature control of the column. We kept the column away from exhaust vents in equipment and observed no detectable change in qualitycontrol values with temperature in routine use over a six- ,, (Figure 3) . However, we have recently found it necessary to run some later columns, prepared from a different lot number of packing material, at 30#{176}C to obtain satisfactory resolution and quality-control values.
Precision. Quality-control samples prepared as described above were analyzed 20 times to obtain within-batch precision and subsequently over the course of 24 batches during 23 weeks. Results are shown in Table 1 .
Stability of hemolysates.
Hemolysates were analyzed and subsequently stored at room temperature (approximately 25 #{176}C) in the wisp sampler for 24-30 h before re-analysis.
Results of the second analysis were not substantially different from those obtained initially. Longer storage at room temperature caused the hemolysates to turn brown, with deterioration in the quality of the chromatography. In contrast, the prepared hemolysate was remarkably stable at 0-4 #{176}C. Over the course of several weeks, we re-assayed the "back-up" aliquots of groups of ifitered hemolysates (see Methods) that had been stored at 0-4 #{176}C after their preparation. Mean values on the day of preparation or several weeks later are shown in Table 2 . Differences between individual analyses were usually small (<0.3%). The HbA1,, fraction in the hemolysate appeared to increase slightly but not significantly on storage. Figure 4 .
Abnormal hemoglobins. The gradient system of Ou et al. (19) , from which this method was derived, was designed to resolve hemoglobin variants. Because our system was designed to measure glycated hemoglobins with maximum throughput, resolution of abnormal hemoglobins ( Figure 5 ) was not as good as in their method. Hemoglobin F ( Figure  5A ) is not resolved from HbA1 in this system, but very few patients over two years of age have more than 0.8% of this ____________ hemoglobin. Heterozygotes for fibS show a split "A0" peak, and the HbA1 is very much lower than that expected for the level of diabetic control as assessed by other criteria ( Figure  SD) . We have assayed blood from one patient with both diabetes and the rare benign hemoglobin D. In that patient we observed 7.4% HbA1,, and a second peak immediately following the HbA1 (presumed to be glycated HbD), which Although this system is not designed to resolve abnormal hemoglobins, we have detected several during the past six months that the method has been in routine use, and the method seems useful in screening for abnormal hemoglobins in patients who may have HbAj values that are very different from those expected from the level of diabetic control as assessed by other criteria. Confirmation of the abnormality may be aided by operating the HPLC with Buffer A only over a 20-30 mm run time. Late-eluting peaks are very broad, but HbA0 is usually separated from other major components. Alternatively, laboratories with gradient systems could investigate these samples further by the method of Ou et al. (19) . Hemoglobin variants differing from Ao at sites that do not affect molecular charge cannot be resolved by HPLC ion-exchange methods, but reversedphase separation of tryptic digests is proving to be a very useful procedure for their identification (34).
